Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers
Recent advancements in nanotechnology have revolutionized cancer therapy—one of the most pressing global health challenges and a leading cause of death—through the development of liposomes (L), lipid-based nanovesicles known for their biocompatibility and ability to encapsulate both hydrophilic and...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/2/245 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849718673557684224 |
|---|---|
| author | Jazmín Torres Johanna Karina Valenzuela Oses Antonio María Rabasco-Álvarez María Luisa González-Rodríguez Mónica Cristina García |
| author_facet | Jazmín Torres Johanna Karina Valenzuela Oses Antonio María Rabasco-Álvarez María Luisa González-Rodríguez Mónica Cristina García |
| author_sort | Jazmín Torres |
| collection | DOAJ |
| description | Recent advancements in nanotechnology have revolutionized cancer therapy—one of the most pressing global health challenges and a leading cause of death—through the development of liposomes (L), lipid-based nanovesicles known for their biocompatibility and ability to encapsulate both hydrophilic and lipophilic drugs. More recent innovations have led to the creation of stimuli-responsive L that release their payloads in response to specific endogenous or exogenous triggers. Dual- and multi-responsive L, which react to multiple stimuli, offer even greater precision, improving therapeutic outcomes while reducing systemic toxicity. Additionally, these smart L can adjust their physicochemical properties and morphology to enable site-specific targeting and controlled drug release, enhancing treatment efficacy while minimizing adverse effects. This review explores the latest advancements in endogenous stimuli-responsive liposomal nanocarriers, as well as dual- and multi-responsive L that integrate internal and external triggers, with a focus on their design strategies, mechanisms, and applications in cancer therapy. |
| format | Article |
| id | doaj-art-fdbeecae4e234c98abec241ea1e40886 |
| institution | DOAJ |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-fdbeecae4e234c98abec241ea1e408862025-08-20T03:12:19ZengMDPI AGPharmaceutics1999-49232025-02-0117224510.3390/pharmaceutics17020245Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced NanocarriersJazmín Torres0Johanna Karina Valenzuela Oses1Antonio María Rabasco-Álvarez2María Luisa González-Rodríguez3Mónica Cristina García4Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre and Medina Allende, Ciudad Universitaria, Science Building 2, Córdoba X5000HUA, ArgentinaDepartamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre and Medina Allende, Ciudad Universitaria, Science Building 2, Córdoba X5000HUA, ArgentinaDepartment of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Universidad de Sevilla, C/Prof. García González 2, 41012 Seville, SpainDepartment of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Universidad de Sevilla, C/Prof. García González 2, 41012 Seville, SpainDepartamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre and Medina Allende, Ciudad Universitaria, Science Building 2, Córdoba X5000HUA, ArgentinaRecent advancements in nanotechnology have revolutionized cancer therapy—one of the most pressing global health challenges and a leading cause of death—through the development of liposomes (L), lipid-based nanovesicles known for their biocompatibility and ability to encapsulate both hydrophilic and lipophilic drugs. More recent innovations have led to the creation of stimuli-responsive L that release their payloads in response to specific endogenous or exogenous triggers. Dual- and multi-responsive L, which react to multiple stimuli, offer even greater precision, improving therapeutic outcomes while reducing systemic toxicity. Additionally, these smart L can adjust their physicochemical properties and morphology to enable site-specific targeting and controlled drug release, enhancing treatment efficacy while minimizing adverse effects. This review explores the latest advancements in endogenous stimuli-responsive liposomal nanocarriers, as well as dual- and multi-responsive L that integrate internal and external triggers, with a focus on their design strategies, mechanisms, and applications in cancer therapy.https://www.mdpi.com/1999-4923/17/2/245lipid vesiclesstimuli-sensitive nanocarrierscancer nanomedicinedrug delivery |
| spellingShingle | Jazmín Torres Johanna Karina Valenzuela Oses Antonio María Rabasco-Álvarez María Luisa González-Rodríguez Mónica Cristina García Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers Pharmaceutics lipid vesicles stimuli-sensitive nanocarriers cancer nanomedicine drug delivery |
| title | Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers |
| title_full | Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers |
| title_fullStr | Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers |
| title_full_unstemmed | Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers |
| title_short | Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers |
| title_sort | innovations in cancer therapy endogenous stimuli responsive liposomes as advanced nanocarriers |
| topic | lipid vesicles stimuli-sensitive nanocarriers cancer nanomedicine drug delivery |
| url | https://www.mdpi.com/1999-4923/17/2/245 |
| work_keys_str_mv | AT jazmintorres innovationsincancertherapyendogenousstimuliresponsiveliposomesasadvancednanocarriers AT johannakarinavalenzuelaoses innovationsincancertherapyendogenousstimuliresponsiveliposomesasadvancednanocarriers AT antoniomariarabascoalvarez innovationsincancertherapyendogenousstimuliresponsiveliposomesasadvancednanocarriers AT marialuisagonzalezrodriguez innovationsincancertherapyendogenousstimuliresponsiveliposomesasadvancednanocarriers AT monicacristinagarcia innovationsincancertherapyendogenousstimuliresponsiveliposomesasadvancednanocarriers |